Please login to the form below

Not currently logged in
Email:
Password:

IQWiG

This page shows the latest IQWiG news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Trump's America First speech, Is Europe's PRIME speeding up drug approvals?

Market access issues remain a major headache for pharma across Europe’s markets, which are increasingly controlled by HTA authorities such as England’s NICE and Germany’s IQWIG.

Latest news

More from news
Approximately 23 fully matching, plus 48 partially matching documents found.

Latest Intelligence

  • The gold standard of scientific evidence The gold standard of scientific evidence

    PBAC appraisals, 64% of NICE appraisals and all IQWiG appraisals relied on RCT-based evidence.

  • Digital disruption Digital disruption

    best patient outcomes - information that would probably come in very handy for submissions to the likes of NICE or IQWiG.

  • Stepping up to payer-driven market access Stepping up to payer-driven market access

    Combined with the demanding - and often less familiar - requirements of the GBA and IQWIG in Germany and other agencies in Europe, these changes make early understanding of the payer environment critical

  • The price is right? The price is right?

    IQWiG evaluations often focus on different patient populations from those used in the clinical trials. ... The dynamic between the G-BA and IQWiG makes pricing and reimbursement an extremely complex process.”.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    After regulatory clarity, the focus will certainly move to health technology assessment bodies, such as Germany's IQWiG and the UK's NICE, if biosimilars' place in clinical practice is to ... For its part IQWiG has yet to assess any biosimilar products.

More from intelligence
Approximately 4 fully matching, plus 18 partially matching documents found.

Latest from PMHub

  • The heart of the matter - Part Three

    In Europe, bodies like NICE and IQWiG are dictating play and exploring new models of assessing the effectiveness of new medicines. ... This is important RWE and IQWiG is now willing to use it for elements of the health economic analysis.”.

  • Oncology drugs under AMNOG

    Usually the G-BA also seeks the advice of expert Health Technology Assessment (HTA) body IQWiG (the Institute for Quality and Efficiency in Healthcare), to determine the level of added benefit ... The G-BA and IQWiG restricted these options to therapies

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics